Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals (MIRM) delivers innovative therapies for rare liver diseases through targeted IBAT inhibitor development. This page provides centralized access to official announcements, clinical trial updates, and strategic developments from the biopharmaceutical innovator.
Investors and healthcare professionals will find timely updates on regulatory milestones, partnership agreements, and pipeline advancements. Our curated feed includes verified press releases about Maralixibat approvals, Volixibat trial progress, and corporate initiatives addressing conditions like progressive familial intrahepatic cholestasis.
Key updates cover FDA communications, research collaborations, and commercialization strategies for orphan drug therapies. All content is sourced directly from Mirum’s disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Mirum’s latest advancements in minimally absorbed liver disease treatments. Check regularly for critical updates impacting clinical development timelines and therapeutic availability.
Mirum Pharmaceuticals reported a total revenue of $12.9 million for Q1 2022, with net product revenue from LIVMARLI® at $10.9 million. This marks significant growth compared to the previous year's figures. Operating expenses decreased to $45.6 million from $47.6 million in Q1 2021. Despite a net loss of $36.6 million (or $1.17 per share), it was an improvement from last year’s loss of $50.5 million. The company anticipates key clinical trial data and regulatory approvals in late 2022, enhancing prospects for future revenue growth.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will report its first quarter financial results on May 5, 2022.
A conference call will be held at 8:30 a.m. ET to discuss the company's progress and priorities for 2022. Investors can join via U.S. toll-free dial-in 844-200-6205 or access the call via webcast. Mirum focuses on rare diseases, with its approved medication LIVMARLI® for cholestatic pruritus in Alagille syndrome. The company is also evaluating investigational treatments for various liver diseases and has submitted a Marketing Authorization Application to the European Medicines Agency.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced on April 8, 2022, that its Compensation Committee granted inducement awards of stock options and restricted stock units to five new employees. The awards comprise 25,500 stock options priced at $27.46 each and 12,650 RSUs. The options will vest over four years, while the RSUs will vest over three years. Mirum focuses on developing treatments for rare diseases, with its marketed drug LIVMARLI® approved for cholestatic pruritus in Alagille syndrome patients. The company also has ongoing clinical trials for additional treatments.
On March 10, 2022, Mirum Pharmaceuticals (NASDAQ: MIRM) granted inducement awards to two new employees, consisting of non-qualified stock options for 16,350 shares and 8,150 restricted stock units (RSUs). The stock options have an exercise price of $21.91, equivalent to the company's closing price on the grant date, and will vest over four years. The RSUs will vest over three years. These grants are part of Mirum's 2020 Inducement Plan and comply with Nasdaq regulations.
Mirum Pharmaceuticals reported a strong start for its product LIVMARLI, generating $3.1 million in net revenue in Q4 2021. Total revenue for 2021 reached $19.1 million. The company anticipates at least $8.0 million in net sales for LIVMARLI in Q1 2022. Major highlights include the sale of a Rare Pediatric Disease Priority Review Voucher for $110 million and a new patent granted for LIVMARLI, providing protection until 2040. The company reported a Q4 net income of $57.5 million, but a net loss for the year of $84 million.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will announce its fourth quarter and year-end 2021 results on March 9, 2022. Following the report, a conference call will be held to discuss the company’s progress and goals for the upcoming year at 4:30 p.m. ET. Investors can join via dial-in or webcast. Mirum focuses on rare diseases, with its approved treatment, LIVMARLI® for cholestatic pruritus in Alagille syndrome. The company is advancing its pipeline with clinical trials for conditions affecting pediatric and adult liver diseases.
On February 10, 2022, Mirum Pharmaceuticals granted inducement awards to two new employees, including non-qualified stock options for 14,200 shares and 7,100 restricted stock units (RSUs) under its 2020 Inducement Plan. The stock options have an exercise price of $22.41, the closing price on the grant date, and vest over four years. The RSUs vest over three years. Mirum, a biopharmaceutical company, focuses on treatments for rare diseases, with an approved drug LIVMARLI for cholestatic pruritus and a late-stage pipeline for liver diseases.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will participate in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The company is scheduled to present on February 16, 2022, at 4:20 p.m. ET. Mirum is focused on developing treatments for rare diseases, including its approved drug LIVMARLI® for Alagille syndrome. The company also has investigational treatments in clinical trials for various liver diseases, demonstrating its commitment to improving patient outcomes in this field.
Mirum Pharmaceuticals (NASDAQ: MIRM) announced an estimated net product revenue of
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) reported that on January 10, 2022, its Compensation Committee granted inducement awards of stock options and restricted stock units to five new employees. The inducement awards consist of 51,700 stock options at an exercise price of $15.50 per share and 7,150 restricted stock units. The stock options vest over four years, while the RSUs vest over three years. These awards aim to attract talent to support Mirum's mission in treating rare diseases, with a focus on the company's approved medication LIVMARLI™ and ongoing clinical trials for other treatments.